Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial.

Clin Kidney J · 2022 · PMC9664584 · PMID 37216675

Europe PMC DOI

hedged sentence

0.3330

closest p · 6.7× alpha

0.3330

boldest claim

The sentences

failed to reach statistical significanceP = .333not close (p > 0.1)

Progression at 12 months was reduced by a mean of 41% [325.8 mm 3 (SE 334.0), model 1] in the vitamin K1 group compared with the control group, but this difference failed to reach statistical significance ( P = .333).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.